Prostate Cancer Nuclear Medicine Diagnostics Market Report

Global and Region Prostate Cancer Nuclear Medicine Diagnostics Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：169
  • REPORT CODE：GMM1008861
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Prostate Cancer Nuclear Medicine Diagnostics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Prostate Cancer Nuclear Medicine Diagnosticsmarket, defines the market attractiveness level of Prostate Cancer Nuclear Medicine Diagnostics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Prostate Cancer Nuclear Medicine Diagnostics industry, describes the types of Prostate Cancer Nuclear Medicine Diagnostics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Prostate Cancer Nuclear Medicine Diagnostics market and the development prospects and opportunities of Prostate Cancer Nuclear Medicine Diagnostics industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Prostate Cancer Nuclear Medicine Diagnostics market in Chapter 13.

    By Player:

    • Telix Pharmaceuticals Ltd

    • Novartis AG

    • Sun Nuclear Corporation

    • Curium Pharma

    • American Pride

    • PETNET Solutions Inc

    • Cardinal Health

    • Blue Earth Diagnostics

    • Lantheus Medical Imagining, Inc

    • NCM-USA LLC

    • Cancer Genetics, Inc

    • Theragnostics Ltd

    • Jubilant Pharma Limited

    • Alliance Medical

    • ImaginAb

    By Type:

    • Single Photon Emission Computed Tomography

    • Positron Emission Tomography

    By End-User:

    • Hospitals

    • Clinics

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Prostate Cancer Nuclear Medicine Diagnostics Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Prostate Cancer Nuclear Medicine Diagnostics Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Prostate Cancer Nuclear Medicine Diagnostics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Prostate Cancer Nuclear Medicine Diagnostics Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Prostate Cancer Nuclear Medicine Diagnostics Market Analysis and Outlook to 2022

    • 7.1 Global Prostate Cancer Nuclear Medicine Diagnostics Consumption (2017-2022)

    • 7.2 United States Prostate Cancer Nuclear Medicine Diagnostics Consumption (2017-2022)

    • 7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Consumption (2017-2022)

    • 7.4 China Prostate Cancer Nuclear Medicine Diagnostics Consumption (2017-2022)

    • 7.5 Japan Prostate Cancer Nuclear Medicine Diagnostics Consumption (2017-2022)

    • 7.6 India Prostate Cancer Nuclear Medicine Diagnostics Consumption (2017-2022)

    • 7.7 South Korea Prostate Cancer Nuclear Medicine Diagnostics Consumption (2017-2022)

    8 Region and Country-wise Prostate Cancer Nuclear Medicine Diagnostics Market Analysis and Outlook to 2028

    • 8.1 Global Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast (2022-2028)

    • 8.2 United States Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast (2022-2028)

    • 8.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast (2022-2028)

    • 8.4 China Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast (2022-2028)

    • 8.5 Japan Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast (2022-2028)

    • 8.6 India Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast (2022-2028)

    • 8.7 South Korea Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast (2022-2028)

    9 Global Prostate Cancer Nuclear Medicine Diagnostics Market Outlook by Types and Applications to 2022

    • 9.1 Global Prostate Cancer Nuclear Medicine Diagnostics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Single Photon Emission Computed Tomography Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Positron Emission Tomography Consumption and Growth Rate (2017-2022)

    • 9.2 Global Prostate Cancer Nuclear Medicine Diagnostics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Prostate Cancer Nuclear Medicine Diagnostics Market Outlook by Types and Applications to 2028

    • 10.1 Global Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Single Photon Emission Computed Tomography Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Positron Emission Tomography Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Prostate Cancer Nuclear Medicine Diagnostics Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Prostate Cancer Nuclear Medicine Diagnostics Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Prostate Cancer Nuclear Medicine Diagnostics Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Prostate Cancer Nuclear Medicine Diagnostics Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Analysis

    • 14.1 Telix Pharmaceuticals Ltd

      • 14.1.1 Telix Pharmaceuticals Ltd Company Details

      • 14.1.2 Telix Pharmaceuticals Ltd Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Telix Pharmaceuticals Ltd Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.2 Novartis AG

      • 14.2.1 Novartis AG Company Details

      • 14.2.2 Novartis AG Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Novartis AG Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.3 Sun Nuclear Corporation

      • 14.3.1 Sun Nuclear Corporation Company Details

      • 14.3.2 Sun Nuclear Corporation Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Sun Nuclear Corporation Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.4 Curium Pharma

      • 14.4.1 Curium Pharma Company Details

      • 14.4.2 Curium Pharma Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Curium Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.5 American Pride

      • 14.5.1 American Pride Company Details

      • 14.5.2 American Pride Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 American Pride Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.6 PETNET Solutions Inc

      • 14.6.1 PETNET Solutions Inc Company Details

      • 14.6.2 PETNET Solutions Inc Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 PETNET Solutions Inc Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.7 Cardinal Health

      • 14.7.1 Cardinal Health Company Details

      • 14.7.2 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.8 Blue Earth Diagnostics

      • 14.8.1 Blue Earth Diagnostics Company Details

      • 14.8.2 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.9 Lantheus Medical Imagining, Inc

      • 14.9.1 Lantheus Medical Imagining, Inc Company Details

      • 14.9.2 Lantheus Medical Imagining, Inc Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Lantheus Medical Imagining, Inc Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.10 NCM-USA LLC

      • 14.10.1 NCM-USA LLC Company Details

      • 14.10.2 NCM-USA LLC Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 NCM-USA LLC Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.11 Cancer Genetics, Inc

      • 14.11.1 Cancer Genetics, Inc Company Details

      • 14.11.2 Cancer Genetics, Inc Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Cancer Genetics, Inc Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.12 Theragnostics Ltd

      • 14.12.1 Theragnostics Ltd Company Details

      • 14.12.2 Theragnostics Ltd Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Theragnostics Ltd Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.13 Jubilant Pharma Limited

      • 14.13.1 Jubilant Pharma Limited Company Details

      • 14.13.2 Jubilant Pharma Limited Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Jubilant Pharma Limited Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.14 Alliance Medical

      • 14.14.1 Alliance Medical Company Details

      • 14.14.2 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • 14.15 ImaginAb

      • 14.15.1 ImaginAb Company Details

      • 14.15.2 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Prostate Cancer Nuclear Medicine Diagnostics

    • Figure Prostate Cancer Nuclear Medicine Diagnostics Picture

    • Table Global Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Prostate Cancer Nuclear Medicine Diagnostics Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Prostate Cancer Nuclear Medicine Diagnostics Consumption by Country (2017-2022)

    • Figure United States Prostate Cancer Nuclear Medicine Diagnostics Consumption and Growth Rate (2017-2022)

    • Table Europe Prostate Cancer Nuclear Medicine Diagnostics Consumption and Growth Rate (2017-2022)

    • Figure China Prostate Cancer Nuclear Medicine Diagnostics Consumption and Growth Rate (2017-2022)

    • Figure Japan Prostate Cancer Nuclear Medicine Diagnostics Consumption and Growth Rate (2017-2022)

    • Figure India Prostate Cancer Nuclear Medicine Diagnostics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Prostate Cancer Nuclear Medicine Diagnostics Consumption and Growth Rate (2017-2022)

    • Figure Global Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast by Country (2022-2028)

    • Figure United States Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Prostate Cancer Nuclear Medicine Diagnostics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Single Photon Emission Computed Tomography Consumption and Growth Rate (2017-2022)

    • Figure Global Positron Emission Tomography Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Single Photon Emission Computed Tomography Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Positron Emission Tomography Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Prostate Cancer Nuclear Medicine Diagnostics Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Prostate Cancer Nuclear Medicine Diagnostics Export by Region (Top 5 Countries) (2017-2028)

    • Table Telix Pharmaceuticals Ltd (Foundation Year, Company Profile and etc.)

    • Table Telix Pharmaceuticals Ltd Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Telix Pharmaceuticals Ltd Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Novartis AG (Foundation Year, Company Profile and etc.)

    • Table Novartis AG Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis AG Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Sun Nuclear Corporation (Foundation Year, Company Profile and etc.)

    • Table Sun Nuclear Corporation Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sun Nuclear Corporation Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Curium Pharma (Foundation Year, Company Profile and etc.)

    • Table Curium Pharma Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Curium Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table American Pride (Foundation Year, Company Profile and etc.)

    • Table American Pride Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table American Pride Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table PETNET Solutions Inc (Foundation Year, Company Profile and etc.)

    • Table PETNET Solutions Inc Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table PETNET Solutions Inc Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Cardinal Health (Foundation Year, Company Profile and etc.)

    • Table Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Blue Earth Diagnostics (Foundation Year, Company Profile and etc.)

    • Table Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Lantheus Medical Imagining, Inc (Foundation Year, Company Profile and etc.)

    • Table Lantheus Medical Imagining, Inc Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lantheus Medical Imagining, Inc Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table NCM-USA LLC (Foundation Year, Company Profile and etc.)

    • Table NCM-USA LLC Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table NCM-USA LLC Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Cancer Genetics, Inc (Foundation Year, Company Profile and etc.)

    • Table Cancer Genetics, Inc Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cancer Genetics, Inc Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Theragnostics Ltd (Foundation Year, Company Profile and etc.)

    • Table Theragnostics Ltd Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Theragnostics Ltd Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Jubilant Pharma Limited (Foundation Year, Company Profile and etc.)

    • Table Jubilant Pharma Limited Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Jubilant Pharma Limited Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table Alliance Medical (Foundation Year, Company Profile and etc.)

    • Table Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product and Service

    • Table ImaginAb (Foundation Year, Company Profile and etc.)

    • Table ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Sales, Price, Value and Gross Profit (2017-2022)

    • Table ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US